Topics and Trends in Most Cited Alzheimer's disease research and treatments Papers

At a glance

Field

Alzheimer's disease research and treatments

Cohort label

Class of 2026 (2024 publications)

Papers analyzed

8,656

Papers ranked

20

Top topics in ranked papers

Amyloid PET, p-tau217, Aβ42/40 ratio, Cerebrospinal fluid biomarkers, Mild cognitive impairment

Publication window

Jan 1, 2024 – Dec 31, 2024

Eligibility

Research articles; reviews excluded

Citation window

18 months post-publication

18m citation range

94–405

Data source

OpenAlex · Retrieved Jul 2026

License

CC BY 4.0

Rankings

20 papers ranked by 18-month citation count

Topic trends

Dominant research themes and year-over-year shifts in Alzheimer's disease research and treatments

What Topics Define the Class of 2026 in Alzheimer's Disease Research?

The Class of 2026 in Alzheimer's disease research is heavily defined by high-precision fluid biomarkers and advanced neuroimaging modalities. Leading the field is Amyloid PET (present in 20% of top-cited publications), reflecting its role as the gold standard for clinical trial stratification and anti-amyloid therapy monitoring. Closely following are blood-based and cerebrospinal fluid (CSF) biomarkers, notably p-tau217 (18%) and the Aβ42/40 ratio (18%), which are revolutionizing early diagnosis and mass screening for preclinical Alzheimer's disease and mild cognitive impairment (14%). In parallel, structural and molecular imaging via Tau PET (12%) provides vital insights into neuropathological staging and cognitive decline correlation. Mechanistic investigations remain anchored in neuroinflammation (14%), microglial activation (8%), and TREM2 variants, alongside preclinical evaluation in transgenic Alzheimer's disease mouse models (10%). Additional emerging themes include oxidative stress (8%) and mitochondrial dysfunction (6%), emphasizing a broader interest in metabolic dysregulation and secondary neurodegenerative cascades. Together, these dominant topics highlight a unified clinical push toward minimally invasive diagnostic panels, automated cutoff validation, and targeted disease-modifying interventions.

How Did Topics Shift from the Class of 2025 to the Class of 2026?

Between the Class of 2025 and the Class of 2026, research priorities in Alzheimer's disease underwent a striking shift from generalized cellular mechanisms to quantitative, clinically actionable diagnostic tools. The most dramatic surging topics were highly specific plasma and imaging markers: Amyloid PET increased its representation from 14% to 20%, while Aβ42/40 ratio expanded from 10% to 18% (an 80% relative growth), and Tau PET doubled from 6% to 12%. Plasma p-tau217 also saw sustained growth (14% to 18%), reflecting rapid widespread clinical adoption of blood-based testing. Furthermore, preclinical validation in mouse models surged fivefold (from 2% to 10%), alongside new focus on oxidative stress (2% to 8%). Conversely, broader diagnostic and pathophysiological descriptors experienced noticeable relative declines. General tau accumulation mentions fell sharply (28% to 12%), neuroinflammation dropped from 18% to 14%, and mild cognitive impairment decreased from 16% to 14%. This transition demonstrates that the field is rapidly progressing beyond broad qualitative labels toward rigorous, standardized biomarker combinations capable of detecting Alzheimer's pathology prior to overt clinical dementia.

Cite this ranking

Pepkio Research Index (PRI). Topics and Trends in Most Cited Alzheimer's disease research and treatments Papers, Class of 2026. https://pri.pepkio.com/top-papers/alzheimer-s-disease-research-and-treatments/2026. Accessed 2026-07-24.

Methodology
Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459

Source data

The full ranking corpus and analysis files are openly available on an external repository. Please cite the dataset below when reusing this data.

Pepkio Research Index (2026). Top papers in Alzheimer's disease research and treatments (Class of 2026) [Data set]. Figshare.

Related rankings

• Neuroscience and Neuropharmacology Research
• Epilepsy research and treatment